

The Canadian National Stock Exchange has not approved nor disapproved the contents of this press release.

MERUS LABS INTERNATIONAL INC.

MERUS LABS INTERNATIONAL INC. ANNOUNCES DIRECTOR APPOINTMENT

VANCOUVER, April 14, 2011

(CNSX: MR)

Merus Labs International Inc. ("Merus" or the "Company") is pleased to announce the appointment of Bob Mehr to its Board of Directors.

Mr. Mehr has nearly 20 years of experience in pharmaceutical retail sales and marketing, as well as hands on management of supply chain and logistics related to retail pharmacy operations. He is presently the CEO of a privately held company managing over \$20 million in annual retail pharmacy sales in the Vancouver and Victoria region that he has owned since 1999.

"Bob brings extensive experience in the pharmaceutical industry to our board of directors," said Ahmad Doroudian, President and Chief Executive Officer of Merus. "He has a strong track record in creating and growing retail pharmacy sales as well as establishing lengthy links within the medical community, both via health professionals and patients. Bob will provide real-time and up to date sales and marketing information as well as feedback from health professionals as it is particularly related to Merus' products which will be of significant value in building and growing our business."

Mr. Mehr is a pharmacist registered with the College of Pharmacists of British Columbia and has a Bachelor of Science degree specializing in pharmacy from the University of British Columbia.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

Forward-looking Statements:

This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with securities regulatory authorities.

For further information please contact:

Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783
adoroudian@meruslabs.com